Introduction
============

Autosomal-dominant familial frontotemporal dementia (FTD) accounts for a large proportion of FTD cases. Mutations in the microtubule associated protein tau (*MAPT*) ([@aws001-B19]) and progranulin (*GRN*) ([@aws001-B6]; [@aws001-B13]) genes account for ∼10--20% of familial cases and are both located on chromosome 17q21. However, a major recent discovery has identified a third gene mutation ([@aws001-B14]; [@aws001-B41]) that appears to be the most common genetic abnormality both in familial FTD and amyotrophic lateral sclerosis (ALS), accounting for 11.7% of familial FTD and 23.5% of familial ALS ([@aws001-B14]). This new mutation is an expansion of a non-coding GGGGCC hexanucleotide repeat in the *C9ORF72* gene and is genetically linked to chromosome 9p ([@aws001-B14]; [@aws001-B41]). Pathologically, both the *GRN* and *C9ORF72* gene mutations are associated with deposition of the transactive response DNA binding protein of 43 kDa (TDP-43), whereas mutations in *MAPT* are associated with deposition of the hyperphosphorylated protein tau.

Previous studies have shown that the most common clinical phenotype associated with both *MAPT* and *GRN* mutations is behavioural variant FTD, although a more varied clinical spectrum has been associated with *GRN* mutations, including diagnoses such as primary progressive aphasia and corticobasal syndrome ([@aws001-B31]; [@aws001-B33]; [@aws001-B7]; [@aws001-B40]; [@aws001-B25]). The *C9ORF72* mutation is also commonly associated with behavioural variant FTD, although also with ALS ([@aws001-B14]; [@aws001-B41]). Neuroanatomical differences have also been identified between the *MAPT* and *GRN* mutations using MRI ([@aws001-B56], [@aws001-B57]; [@aws001-B44]). Mutations in *MAPT* have been associated with atrophy predominantly in the anteromedial temporal lobes ([@aws001-B60], [@aws001-B56], [@aws001-B57]; [@aws001-B17]; [@aws001-B49]; [@aws001-B44]), whereas mutations in *GRN* have been associated with more widespread and asymmetric patterns of atrophy that involve the frontal, temporal and parietal lobes ([@aws001-B55], [@aws001-B57]; [@aws001-B7]; [@aws001-B44]). These findings suggest that imaging could be useful to help predict the specific mutation, and hence the underlying pathology. Importantly, characterizing the patterns of atrophy associated with these mutations also provides important insight into the biology of the disease and helps to further define neuroanatomical correlations with clinical and pathological features in FTD. No studies have yet assessed patterns of atrophy in the *C9ORF72* mutation, and hence it is unknown whether the neuroanatomical signature of this mutation differs from *MAPT* and *GRN* mutations.

The aim of our study was therefore to determine the pattern of brain atrophy associated with *C9ORF72*, and to determine which regions best differentiate *C9ORF72* from *MAPT* and *GRN*, as well as from sporadic FTD including ALS. Furthermore, although *MAPT* and *GRN* mutations have been associated with differing clinical and neuroanatomical features, a number of studies have highlighted a high degree of variability within subjects with each of these mutations, as well as within subjects, within the same family ([@aws001-B53]; [@aws001-B20]; [@aws001-B9]; [@aws001-B25]). Therefore, we also aimed to assess the degree of neuroanatomical variability within each of the genetic mutations and sporadic FTD, in order to determine whether variability in the new *C9ORF72* gene mutation is comparable with the other groups.

Materials and methods
=====================

Subjects
--------

We identified all subjects seen at Mayo Clinic, Rochester, MN, USA who had screened positive for mutations in *C9ORF72* with a volumetric MRI. A total of 19 subjects, representing 16 families, were identified.

We then identified three disease comparison groups. First, we identified all subjects who had screened positive for mutations in *GRN* or *MAPT* with volumetric MRI. Since all *C9ORF72* subjects had a clinical diagnosis of behavioural variant FTD we only included *GRN* or *MAPT* subjects that also fulfilled clinical criteria for behavioural variant FTD ([@aws001-B38]). Eighteen subjects were identified with *GRN* mutations. Six subjects were excluded due to other clinical diagnoses \[four with primary progressive aphasia ([@aws001-B34]), one with corticobasal syndrome ([@aws001-B8]) and one with Alzheimer\'s dementia ([@aws001-B32])\], resulting in a total of 12 subjects, representing six families, with behavioural variant FTD that were included in the study. Five different *GRN* mutations were present in our cohort: c.154delA (p.Thr52HisfsX2), c.910_911insTG (p.Trp304LeufsX58), c.1395_1396insC (p.Cys466LeufsX46), c.1145delC (p.Thr382SerfsX30) and c.138+1G\>A (IVS1+1G\>A). Twenty-six subjects were identified with *MAPT* mutations. One subject with a clinical diagnosis of primary progressive aphasia ([@aws001-B34]) was excluded, resulting in 25 subjects with behavioural variant FTD, representing 12 families that were included in the study. Nine different *MAPT* mutations were present in our cohort: P301L (c.1907C\>T;p.Pro301Leu), IVS10+16 (c.1920+16C\>T;IVS10+16C\>T), IVS10+3 (c.1920+3G\>A;IVS10+3G\>A), N279K (c.1842T\>G;p.Asn279Lys), V337M (c.2014G\>A; Val337Met), S305N (c.1919G\>A;p.Ser305Asn) ([@aws001-B9]), G389R (c.2170G\>A;p.Gly389Arg), R406W (c.2221C\>T;p.Arg406Trp) and IVS9-10 (c.1827-10G\>T;IVS9-10G\>T) ([@aws001-B30]). In all cases, the first MRI that was performed after the subject had a dementia diagnosis was used.

Secondly, the *C9ORF72* group was age- and gender-matched to a group of 20 subjects with behavioural variant FTD ([@aws001-B38]) that included 50% that had clinicopathological evidence of ALS ([@aws001-B22]). This was important as some *C9ORF72* subjects also had clinicopathological evidence of ALS. These subjects did not have family history of either an FTD syndrome or ALS in a first- or second-degree relative, and were screened negative for genetic mutations, and hence were considered to have sporadic behavioural variant FTD.

The majority of subjects had been prospectively studied in our Alzheimer\'s Disease Research Centre (ADRC). Clinical diagnoses were made according to consensus criteria for behavioural variant FTD ([@aws001-B38]), primary progressive aphasia ([@aws001-B34]), corticobasal syndrome ([@aws001-B8]) and Alzheimer\'s dementia ([@aws001-B32]). Diagnoses were retrospectively fitted for 10/76 cases that met Lund--Manchester criteria for FTD ([@aws001-B51]). Imaging results have previously been published from seven of the *GRN* subjects and 22 of the *MAPT* subjects ([@aws001-B55]). The total cohort of 76 FTD cases was frequency matched by age, gender and MRI field strength to a cohort of 40 cognitively normal control subjects. Subject demographics for all groups are shown in [Table 1](#aws001-T1){ref-type="table"}. Informed consent was obtained from all subjects and/or their proxies for participation in the studies, which were approved by the Mayo Institutional Review Board. Table 1Subject demographicsDemographicsControls*MAPTGRNC9ORF72*Sporadic FTD*P*-values across disease groups*n*4025121920NAGender, female, *n* (%)20 (50)12 (48)6 (50)10 (53)10 (50)0.99Education (years)15 (10--20)14.0 (9--19)14.0 (12--20)14.0 (12--20)15.0 (11--18)0.76Age at onset (years)NA43.4 (21--63)56.0 (47--83)51.0 (33--67)51.5 (38--62)\<0.0001Age at death (years)[^a^](#aws001-TF1){ref-type="table-fn"}NA55.3 (42--70)64.1 (57--87)56.5 (35--75)58.3 (43--70)0.08Disease duration (years)NA8.0 (4--21)7.0 (5--10)5.5 (2--12)4.4 (1--15)0.17Age at scan (years)58.0 (34--84)51.6 (25--65)62.6 (50--84)54.8 (35--70)54.5 (41--67)0.01[^b^](#aws001-TF2){ref-type="table-fn"}Onset to scan (years)NA5.0 (0.2--24)2.7 (1.3--7.1)2.7 (1.2--15.0)2.0 (0--6)0.08[^1][^2][^3]

Genetic analysis
----------------

Exons 0--12 and the 3′-untranslated region of the *GRN* gene were amplified by polymerase chain reaction using our previously published primers and protocol ([@aws001-B6]; [@aws001-B16]). Analysis of *MAPT* exons 1, 7 and 9--13 was also performed using primers and conditions that were previously described ([@aws001-B19]). For *GRN* and *MAPT*, the polymerase chain reaction amplicons were purified using the Multiscreen system (Millipore) and then sequenced in both directions using Big Dye® chemistry following manufacturer\'s protocol (Applied Biosystems). Sequence products were purified using the Montage system (Millipore) prior to being run on an ABI 3730 DNA Analyzer. Sequence data were analysed using either SeqScape or Sequencher software. To determine the presence of an expanded GGGGCC hexanucleotide repeat in *C9ORF72*, we used the repeat primed polymerase chain reaction method previously published ([@aws001-B14]).

Pathological analysis
---------------------

Neuropathological examinations were performed according to the Consortium to Establish a Registry for Alzheimer\'s Disease (CERAD) recommendations ([@aws001-B35]). Pathological assessment and diagnosis was conducted by one of two expert neuropathologists (D.W.D. or J.E.P.). All cases were reclassified based on recent consensus recommendations for neuropathological subtypes of frontotemporal lobar degeneration (FTLD) ([@aws001-B29]). Cases were classified according to abnormal protein into FTLD with tau immunoreactive inclusions (FTLD-tau), FTLD with TDP-43 (FTLD-TDP) and FTLD with fused in sarcoma (FTLD-FUS). FTLD-TDP was subclassified into types 1--3 according to [@aws001-B27]).

Magnetic resonance imaging analysis
-----------------------------------

### Magnetic resonance imaging protocol

All subjects underwent a standardized protocol head MRI that included a T~1~-weighted 3D volumetric sequence. In the majority of cases this consisted of a spoiled gradient echo sequence performed at 1.5T, although 35% of *C9ORF72*, 32% of *MAPT*, 33% of *GRN*, 20% of sporadic FTD and 37% controls had a magnetization-prepared rapid acquisition gradient echo sequence performed at 3T. All images underwent pre-processing that included corrections for gradient non-linearity ([@aws001-B24]) and intensity inhomogeneity using both the N3 bias correction ([@aws001-B47]) followed by the SPM5-based bias correction.

### Voxel-based morphometry

Patterns of grey matter atrophy were assessed using the automated and unbiased technique of voxel-based morphometry ([@aws001-B4]). An optimized method of voxel-based morphometry was applied using both customized templates and prior probability maps ([@aws001-B46]), implemented using SPM5 (<http://www.fil.ion.ucl.ac.uk/spm>). Briefly, all images were normalized to a customized template and segmented using unified segmentation ([@aws001-B5]), followed by the hidden Markov random-field clean-up step ([@aws001-B62]). All images were modulated and smoothed with an 8-mm full-width at half-maximum smoothing kernel. A full factorial statistical model was used to assess patterns of grey matter loss in each disease group compared with controls. The *C9ORF72* group was also compared directly with *MAPT*, *GRN* and sporadic FTD. Age at scan, gender, total intracranial volume and field strength were included as covariates in the statistical model. Results were assessed after correction for multiple comparisons using the family-wise error correction at *P \< *0.05. Comparisons across disease groups were investigated uncorrected for multiple comparisons at *P \< *0.001.

### Atlas-based parcellation

Atlas-based parcellation was employed using SPM5 and an in-house modified version of the automated anatomic labelling atlas ([@aws001-B52]), as previously described ([@aws001-B61]), in order to generate grey matter volumes for 37 regions of interest that covered cortical and subcortical grey matter: left and right dorsolateral frontal, medial frontal, orbitofrontal, sensorimotor, inferior temporal (fusiform + inferior temporal gyrus), lateral temporal (middle + superior temporal gyri), medial temporal (amygdala + hippocampus), temporal pole, lateral parietal, precuneus, occipital lobe, anterior cingulate, middle cingulate, posterior cingulate, insula, thalamus, striatum (caudate + putamen), cerebellum and total vermis.

Whole-brain volume and total intracranial volume estimates were obtained by propagating region of interest masks from a template. All regional grey matter volumes were divided by whole brain volume to correct for differences in global atrophy between subjects. This step was performed because we were interested in assessing the relative involvement of each region, without confounds of global severity. In addition, an asymmetry score was calculated for the frontal, temporal and parietal lobes for each subject as follows: (left volume − right volume)\*2/(left volume + right volume).

Statistics
----------

All statistical analyses were performed using R version 2.13.2 (<http://www.R-project.org>) and the glmnet package version 1.7.1. Comparisons of demographic and clinical variables of interest among groups were performed using Kruskal--Wallis tests for continuous variables and chi-squared or Fisher\'s exact tests for categorical variables.

Four-category multinomial logistic regression was used to discriminate among the four disease groups ([@aws001-B1]) using whole brain volume-corrected volumes of the 37 regions of interest and frontal lobe asymmetry score as predictors. Due to the large number of predictors relative to the sample size, we used the elastic net penalization approach to develop a parsimonious multivariable model ([@aws001-B15]).

In multivariable modelling, the degree of overfitting depends on the number of variables considered rather than the number of variables in the final model ([@aws001-B18]). Roughly speaking, in traditional model-selection techniques, and in particular with step-wise variable selection, when a large number of variables are considered, the most significant variables are included 'as is' even though they are very likely overfitting to the sample and thus overestimates of the magnitude of the association. This is due to the regression to the mean phenomena; in a different sample, such variables would likely still show an association but probably to a lesser degree. In repeated sample, the coefficients would tend to regress to their 'rightful place'. Penalization methods 'shrink' regression coefficients towards zero as a way to reduce the effect of extreme coefficients and the resulting bias that is present in overfitting. In a sense, penalized methods are used to help the coefficients find their rightful place by penalizing those that are overly large. In the following paragraph, we describe how the penalty was applied and how the specific value of the penalty was chosen.

The elastic net penalization approach we used is a combination of ridge regression penalization, where the sum of the squares of the coefficients are controlled, and the lasso penalty, where the sum of the absolute values of the coefficients are controlled. The elastic net requires the analyst to select two tuning parameters. The first, α, was set to 0.9, so that the lasso penalty was predominant but there remained a degree of ridge regression, a balance that tends to perform well when there are a large number of possibly correlated predictors ([@aws001-B15]). The second parameter, λ, determines the degree of penalization and can range from zero corresponding to an unpenalized full model up to infinity corresponding to a model in which all non-intercept coefficients are shrunk to zero. We selected λ to optimize goodness of fit using the multinomial deviance based on leave-one-out cross-validation. Informally, the method omitted a subject from the sample, fit the model for 100 different values λ and calculated the goodness-of-fit error for each value of λ. After doing this 76 times, we obtained 76 estimates of goodness-of-fit error at each value of λ and from these the mean and SD errors are calculated. The value of λ corresponding to where the mean error was smallest defined the 'optimal' model in terms of cross-validation. That is, the model that is likely to be most generalizable. To be conservative, our final model was chosen based on the '1SE rule' in which we selected the largest λ value, or equivalently the most parsimonious model, such that the goodness-of-fit error was still within 1 standard error (1SE) of the optimum.

In order to assess the dimensionality of the imaging data in each disease group, principal component analysis was performed within the *C9ORF72*, *MAPT, GRN* and sporadic FTD groups separately using the whole brain volume-corrected volumes of the 37 regions of interest, and the frontal lobe asymmetry score.

Results
=======

Clinical, demographic and pathological findings
-----------------------------------------------

Significant differences were observed in age at onset and MRI across disease groups, with the youngest median age observed in *MAPT*, and oldest age observed in *GRN* ([Table 1](#aws001-T1){ref-type="table"}). No differences were observed across disease groups in gender, education, disease duration, age at death or time from onset to MRI. The degree of cognitive, functional and behavioural impairment, as well as the degree of parkinsonism, also did not differ across groups ([Table 2](#aws001-T2){ref-type="table"}). The *C9ORF72* mutation was associated with behavioural variant FTD. Two subjects had co-existing ALS ([Table 2](#aws001-T2){ref-type="table"}). None of the *MAPT* or *GRN* subjects had ALS. Although pathology was not available for all subjects, the pathological diagnoses were strikingly different ([Table 2](#aws001-T2){ref-type="table"}). The *C9ORF72* mutation was associated with FTLD-TDP types 1 ([@aws001-B27]) (harmonized type A; [@aws001-B28]) and 3 ([@aws001-B27]) (harmonized type B; [@aws001-B28]) and a pathological diagnosis of ALS. This contrasted with *GRN* that was associated with only FTLD-TDP type 1 ([@aws001-B27]), and *MAPT* that was associated with FTLD-tau. By design, the sporadic FTD group consisted of subjects with behavioural variant FTD of which 50% had clinicopathological evidence of ALS (FTLD-TDP type; [@aws001-B27]). Table 2Clinical, pathological and imaging featuresFeaturesControls*MAPTGRNC9ORF72*Sporadic FTD*P*-values across disease groups*n*4025121920NAMMSE at scan30 (25--30)25.0 (1--30)19.0 (4--27)25.0 (11--29)25.0 (2--30)0.16[^a^](#aws001-TF3){ref-type="table-fn"}CDR-SB at scan0 (0--0)5.5 (0.5--18)7.0 (4.5--18)5.0 (1--18)6.5 (2--12)0.28[^a^](#aws001-TF3){ref-type="table-fn"}UPDRS at scan0.0 (0--2)2.5 (0--48)4.0 (0--25)0.0 (0--15)1.0 (0--9)0.43[^a^](#aws001-TF3){ref-type="table-fn"}NPI-Q at scan0.0 (0--3)8.0 (1--20)7.0 (2--18)8.0 (2--24)11 (1--22)0.78[^a^](#aws001-TF3){ref-type="table-fn"}Presence/absence of clinical features at scan    Amyotrophic lateral sclerosis, *n* (%)0 (0)0 (0)0 (0)2 (11)7 (35)NA    Cerebellar ataxia, *n* (%)0 (0)0 (0)0 (0)0 (0)0 (0)NA    Limb apraxia, *n* (%)0 (0)0 (0)0 (0)0 (0)0 (0)NA    Autonomic dysfunction, *n* (%)0 (0)0 (0)0 (0)0 (0)0 (0)NAPathological diagnoses    FTLD-TauNA6003\<0.0001    FTLD-FUSNA0001    FTLD-TDP type 1NA085 (2 with ALS)0    FTLD-TDP type 3NA003 (2 with ALS)8 (6 with ALS)Asymmetry score    Frontal lobe0.050.060.210.060.080.0035[^a^](#aws001-TF3){ref-type="table-fn"}    Temporal lobe0.060.110.200.080.090.0083[^a^](#aws001-TF3){ref-type="table-fn"}    Parietal lobe0.040.070.130.050.070.0003[^a^](#aws001-TF3){ref-type="table-fn"}[^4][^5][^6]

Patterns of atrophy
-------------------

Patterns of regional atrophy compared with controls as revealed by voxel-based morphometry can be observed in [Fig. 1](#aws001-F1){ref-type="fig"}A, and the regional volumes for all disease groups are shown in [Figs 2](#aws001-F2){ref-type="fig"} and [3](#aws001-F3){ref-type="fig"}. The *C9ORF72* group showed a widespread pattern of grey matter loss compared with controls. The most striking loss was observed in frontal lobes, involving orbitofrontal, medial and dorsolateral regions, followed by temporal lobes. Loss was also observed in parietal and occipital lobes and in cerebellum. Patterns of loss observed in *MAPT* and *GRN* were typical of those we have previously published ([@aws001-B57]), with striking temporal lobe volume loss observed in *MAPT* and temporoparietal loss observed in *GRN*. The sporadic FTD group showed predominant frontal lobe atrophy, with only mild temporal involvement. Figure 1Results of the voxel-based morphometry analysis of grey matter volume. (**A**) Patterns of grey matter loss in *MAPT*, *GRN*, *C9ORF72* and sporadic FTD groups compared with controls, at *P \< *0.05 (corrected for multiple comparisons using family-wise error). (**B**) Differences in grey matter volume between the *C9ORF72* group and the other disease groups, at *P \< *0.001 (uncorrected for multiple comparisons). Results are shown in 3D renderings of the brain. Figure 2Box plots of all variables selected in the penalized multinomial logistic regression model as best for differentiating disease groups. All regional grey matter volumes were divided by whole brain volume to correct for differences in global atrophy between subjects. This step was performed because we were interested in assessing the relative involvement of each region, without confounds of global severity. L = left; R = right; ROI = region of interest. Figure 3Box plots of variables that were not selected in the penalized multinomial logistic regression model as useful for differentiating disease groups, and hence not shown in [Fig. 2](#aws001-F2){ref-type="fig"}. All regional grey matter volumes were divided by whole brain volume to correct for differences in global atrophy between subjects. This step was performed because we were interested in assessing the relative involvement of each region, without confounds of global severity. L = left; R = right; ROI = region of interest.

On direct comparison across groups ([Fig. 1](#aws001-F1){ref-type="fig"}B), *C9ORF72* showed greater loss in parietal and occipital lobes, particularly medially, as well as lateral inferior frontal lobe and cerebellum, compared with *MAPT* and sporadic FTD. Conversely, *MAPT* showed greater grey matter loss throughout the anterior temporal lobes, bilaterally, compared with *C9ORF72*. The *C9ORF72* group did not show any regions of greater loss than *GRN*, although *GRN* showed greater involvement of left inferior temporal lobe and bilateral parietal lobe than *C9ORF72*. The sporadic FTD group only showed a small region of greater loss than *C9ORF72* in the medial frontal lobe.

Asymmetry
---------

The degree of frontal, temporal and parietal asymmetry differed across disease groups ([Table 2](#aws001-T2){ref-type="table"}), with greatest asymmetry observed in the *GRN* group across all three regions. The *C9ORF72* group was not associated with asymmetry in any region.

Classification accuracy
-----------------------

The optimal penalized multinomial logistic regression model was able to accurately classify 71/76 (93%) subjects using 26 variables ([Table 3](#aws001-T3){ref-type="table"}). In a more conservative model that required only 14 variables and hence potentially more clinically meaningful, the regression model was still able to correctly classify 56/76 (74%) subjects ([Table 3](#aws001-T3){ref-type="table"}). Box plots of these 14 variables are shown in [Fig. 2](#aws001-F2){ref-type="fig"} and the regression coefficients of the 14 variables are summarized graphically in [Fig. 4](#aws001-F4){ref-type="fig"}. The predictive value of each variable is demonstrated in [Fig. 5](#aws001-F5){ref-type="fig"}. Small volumes of left sensorimotor cortices, right occipital lobe and left cerebellum, and relatively large volumes of left inferior temporal lobe were independently predictive of *C9ORF72*; small volumes of inferior temporal lobe and large volumes of right dorsolateral frontal lobe, parietal lobe and left occipital lobe were independently predictive of *MAPT*; small volumes of right lateral parietal lobe were independently predictive of *GRN*; and small volumes of dorsolateral frontal lobes and large volumes of left lateral temporal lobe were independently predictive of sporadic FTD. Figure 4Coefficients for the 14 variables that were retained in the final penalized multinomial logistic regression for the *MAPT*, *GRN*, *C9ORF72* and sporadic FTD groups. A negative coefficient means that lower values (i.e. more atrophy) on that variable increases the estimated probability of being in that group, holding all other variables constant. L = left; R = right. Figure 5Plots showing the estimated probability of *MAPT*, *GRN*, *C9ORF72* and sporadic FTD according to volume for each of the 14 variables that were retained in the final model. In each panel, the adjustment covariates are set to their mean values. L = left; R = right; ROI = region of interest. Table 3Classification tables for both the optimum and conservative penalized multinomial logistic regression modelsPredicted patient groups*MAPT* (*n* = 25)*GRN* (*n* = 12)*C9ORF72* (*n* = 19)Sporadic FTD (*n* = 20)Optimal model with 26 variables (overall classification 93%)    *MAPT*24001    *GRN*01200    *C9ORF72*00171    Sporadic FTD10218Conservative model with 14 variables (overall classification 74%)    *MAPT*23303    *GRN*0710    *C9ORF72*11134    Sporadic FTD11513

Variability within groups
-------------------------

The results of the within-group principal component analysis are shown in [Fig. 6](#aws001-F6){ref-type="fig"}. Approximately six principal components explained 80% of the variability in the imaging data in all four groups. In addition, the percentage of variability explained by each principal component was similar across groups. Figure 6Plot of the cumulative proportion of variability explained by each principal component for the *C9ORF72*, *MAPT*, *GRN* and sporadic FTD groups.

Discussion
==========

This study demonstrates that the newly discovered mutation in the *C9ORF72* gene is associated with predominant frontal lobe atrophy, with involvement of the anterior temporal, parietal lobes and cerebellum. This specific pattern differed from that observed in *MAPT* and *GRN* mutations, and sporadic behavioural variant FTD. These patterns of regional atrophy accurately classified the majority of *C9ORF72*, *MAPT*, *GRN* and sporadic FTD subjects at the single-subject level.

Widespread and severe patterns of atrophy were observed in *C9ORF72*, although the most striking atrophy was observed in frontal lobes, followed by anterior temporal lobes. Frontal atrophy was not focal and involved medial, dorsolateral and orbitofrontal regions, demonstrating the lack of regional specificity within the frontal lobe for this mutation. In addition, we identified parietal lobe atrophy. Once again, parietal atrophy was not focal and involved medial and lateral regions. Involvement of both lateral and medial parietal lobes is unusual in FTD, and hence may be particularly associated with this mutation. Even more unusual was the identification of atrophy of the cerebellum, which has not been emphasized in any clinical or pathological FTD variants. This finding is intriguing since a family with the *C9ORF72* gene mutation was found to exhibit numerous neuronal cytoplasmic inclusions and short neurites in the granule cell layer of the cerebellar cortex ([@aws001-B10]); a finding that has now been confirmed in two recent studies assessing relatively large cohorts of subjects with the *C9ORF72* gene mutation that also identified cerebellar inclusions ([@aws001-B2]; [@aws001-B37]). Therefore, cerebellar pathology, both macroscopic and microscopic, could be a characteristic feature of *C9ORF72*. Cerebellar clinical signs, such as ataxia, were not recorded in our *C9ORF72* subjects, although cerebellar ataxia has been observed previously in a family with chromosome 9 mutations ([@aws001-B39]). It is possible that cerebellar signs are absent in our study but it is also possible that cerebellar signs are present, yet not recorded. Regardless, the imaging findings of cerebellar atrophy in this study, supports the notion that future prospective studies should include standardized neurological evaluations of the cerebellar system. It would also appear surprising that we did not observe significant atrophy of the primary motor cortex in *C9ORF72*; however, it must be emphasized that only two of our *C9ORF72* subjects had clinical evidence of ALS. Furthermore, previous imaging studies have similarly not identified atrophy or hypometabolism in the primary motor cortex of subjects with FTD with ALS ([@aws001-B21]; [@aws001-B59]; [@aws001-B10]). It is possible that diffusion tensor imaging assessment of specific white matter tracts may be more sensitive to deficits in primary motor regions, or to loss of projection fibres originating from the primary motor cortex in FTD subjects with ALS ([@aws001-B54]).

The specific pathological diagnoses associated with *C9ORF72* were FTLD-TDP types 1 and 3. Both of these pathologies are associated with frontotemporal atrophy, with a frontal predominance in type 3 and parietal involvement in type 1 ([@aws001-B43]; [@aws001-B58]). Hence, the patterns we observe in *C9ORF72* may be driven by a combination of these pathologies. Neither of these two pathologies, however, has been associated with cerebellar atrophy, which is not necessarily surprising since previous studies would not have stratified FTLD-TDP types by specific mutation type. More specifically, previous studies assessing FTLD-TDP type 1 would have grouped cases with *C9ORF72*, with *GRN* mutation cases, and with cases with neither mutation.

The patterns observed in *C9ORF72* contrasted with *MAPT* mutations, in which the most striking atrophy occurred in anteromedial temporal lobes and with *GRN* mutations where the most striking atrophy occurred in temporal and parietal lobes. These findings confirm our previous studies of *MAPT* and *GRN* using many of the same subjects ([@aws001-B56], [@aws001-B57]) and previous studies using independent cohorts that have associated *MAPT* mutations with anteromedial temporal atrophy ([@aws001-B3]; [@aws001-B49]; [@aws001-B36]; [@aws001-B44]; [@aws001-B45]) and *GRN* mutations with parietal atrophy ([@aws001-B50]; [@aws001-B12]; [@aws001-B44]; [@aws001-B45]), despite clinical variability across studies. Both *MAPT* and *GRN* showed significantly greater temporal lobe involvement than *C9ORF72*, with the temporal involvement focused on anteromedial regions in *MAPT* and inferior temporal lobe in *GRN*. This result helps to further clarify our previous finding that subjects with FTLD-TDP type 1 with *GRN* mutations have greater lateral temporal atrophy than those without *GRN* mutations ([@aws001-B58]); we now know that many of the *GRN* negative FTLD-TDP type 1 subjects in our cohort have *C9ORF72* mutations. Although all the *MAPT* subjects had a clinical diagnosis of behavioural variant FTD, semantic deficits are common ([@aws001-B42]; [@aws001-B48]; [@aws001-B40]), concurring with the anteromedial involvement. The *C9ORF72* group did, however, show significant atrophy in posterior regions of the brain, which is distinct from *MAPT* and sporadic FTD, but similar to *GRN*. Both *GRN* and *C9ORF72* gene mutations are associated with FTLD-TDP type 1 pathology as mentioned earlier, and this pathology is particularly associated with atrophy in posterior regions of the brain ([@aws001-B58]). Atrophy of the cerebellum was not observed in the *MAPT* group; with *C9ORF72* showing significantly greater cerebellar atrophy than the *MAPT* subjects. Cerebellar atrophy was however observed, although to a lesser degree, in the *GRN* group, again suggesting a possible link to FTLD-TDP type 1 pathology. Another important feature of the *C9ORF72* mutation was that it was associated with relatively symmetric patterns of frontal, temporal and parietal atrophy at the group level. In contrast, *GRN* mutations were associated with asymmetric patterns of atrophy, as previously noted ([@aws001-B7]; [@aws001-B17]; [@aws001-B26]; [@aws001-B25]). The *C9ORF72* gene mutation showed a different pattern of atrophy from sporadic FTD in spite of the fact that both groups consisted of subjects with behavioural variant FTD with and without ALS. Both groups showed striking frontal lobe atrophy, which is not surprising given the clinical diagnoses ([@aws001-B11]; [@aws001-B21]; [@aws001-B59]), although greater involvement of posterior cortices and cerebellum was observed in *C9ORF72*. These findings argue that genetics has a strong influence over patterns of neuroanatomical damage in FTD and suggest that each disease group has a different path of pathological progression through the brain.

We have demonstrated that these neuroanatomical differences across groups could classify the subjects in our cohort at the individual level. The penalized multinomial logistic regression model showed that atrophy of sensorimotor cortex, precuneus, occipital lobe and cerebellum, with sparing of the inferior temporal lobe, was particularly useful to help predict the presence of the *C9ORF72* gene mutation in the context of *MAPT, GRN* and sporadic FTD. Although the sensorimotor cortex and occipital lobes were not the most heavily affected regions in *C9ORF72*, they were relatively more affected than in the other groups, and hence useful for differentiation.

These findings further validate the differences observed at the group level. Furthermore, they suggest that patterns of atrophy have the potential to be useful to help differentiate these groups and help predict the presence of the *C9ORF72* gene mutation in subjects with behavioural variant FTD, regardless of the presence of family history. This is particularly useful since the pathologies underlying behavioural variant FTD are notoriously heterogeneous and difficult to predict based on clinical features alone ([@aws001-B23]). The findings could help, for example, to tailor an approach to genetic testing to avoid performing costly and unnecessary multiple genetic tests. Taken into context, if a patient presents to the clinic with behavioural variant FTD the easiest mutation to identify, or rule out, using MRI appears to be mutations in *MAPT* since it is the only group in which atrophy predominantly and focally affects the anteromedial temporal lobes. If a mutation in *MAPT* can be ruled out, our data suggest that it would then be helpful to assess the degree of involvement of the lateral temporal and parietal lobes. If these regions are affected, then one would suspect either a *GRN* or *C9ORF72* mutation, since atrophy in sporadic FTD does not tend to heavily involve these regions. The differentiation of *C9ORF72* and *GRN* appears to be more challenging due to the degree of overlap observed in these groups, although there is a suggestion that greater involvement of the sensorimotor cortices and occipital lobe would suggest *C9ORF72*, while striking atrophy of the parietal lobe would be more suggestive of *GRN*.

All four disease groups showed some involvement of the frontal lobes so it may be difficult to differentiate groups based only on this region; however, the absence of frontal atrophy would point towards a *MAPT* mutation and striking dorsolateral frontal atrophy would more suggest sporadic FTD. An important point to stress is that the regional volumes used in our model were divided by the size of the brain to allow us to assess the relative involvement of each region, without confounds of global severity. It is therefore important when assessing these patients to not just look at the degree of atrophy but to instead assess the relative involvement of each region in comparison with other regions of the brain. Therefore, a *GRN* subject that is early in the disease course may have the same amount of parietal involvement as a *C9ORF72* subject later in the disease course, but importantly *GRN* would still have relatively greater involvement of the parietal lobe compared with other regions. One caveat to take into account, however, is that differentiation is likely to be much more difficult in patients with advanced disease since regions that were previously unaffected may start to 'catch up' to the regions that showed a greater degree of atrophy early in the disease, resulting in a less focal pattern of loss. Imaging is therefore most likely to be helpful early in the disease course.

It is important to point out that while our analysis focused only on imaging, the addition of clinical features will even further improve prediction. The presence of a strong family history argues against sporadic FTD; the presence of ALS is very suggestive of the *C9ORF72* mutation ([@aws001-B14]; [@aws001-B41]), rather than either *MAPT* or *GRN*; young age would be particularly suggestive of a *MAPT* mutation, and older age of *GRN* mutations ([@aws001-B7]; [@aws001-B40]; [@aws001-B57]). Ultimately, optimum prediction is likely to require both imaging and clinical information.

While there could be concern that the results of our model are specific to the subjects in our study and not generalizable to the population, we specifically chose penalization methods, instead of more traditional regression methodology, with leave-one-out cross-validation, since it is a good way to fit a model that generalizes well to the population rather than to a particular set of patients. We therefore do not think that the classification rates are over estimates based on the patients in the sample but are instead reflective of the population. We acknowledge that due to sampling variability the classification rates are estimates only, but because of our methods and choice of a conservative model, we do not think they are biased.

We also demonstrated that the dimensionality or richness of the imaging data did not differ across these groups, and hence the imaging data in each group was similarly varied and similarly complex. The *C9ORF72* group therefore does not appear to be more heterogeneous than the other groups. Anatomical heterogeneity has been previously reported in *GRN* and *MAPT* cohorts and families, although these cohorts often included subjects with varying clinical diagnoses ([@aws001-B53]; [@aws001-B20]; [@aws001-B9]; [@aws001-B25]). Our findings show that the degree of heterogeneity associated with these mutations in behavioural variant FTD is very similar to that observed in a typical sporadic FTD cohort.

This study describes for the first time the patterns of atrophy associated with the newly discovered *C9ORF72* gene mutation. These findings provide important understanding of the biology of these mutations, have the potential to be useful clinically and will likely pave the way for future studies that further investigate neuroanatomical correlations with clinical and pathological features.
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ALS

:   amyotrophic lateral sclerosis

FTD

:   frontotemporal dementia

FTLD

:   frontotemporal lobar degeneration

GRN

:   progranulin

MAPT

:   microtubule-associated protein tau

TDP-43

:   transactive response DNA binding protein of 43 kDa

[^1]: Data are shown as median (range). NA = not applicable.

[^2]: a A total of 10 subjects with the *C9ORF72* mutation, 14 subjects with the *MAPT* mutation, 8 subjects with the *GRN* mutation, and 14 sporadic FTD have died.

[^3]: b Significant differences were observed when including controls, at *P  \<*0.05.

[^4]: Data are shown as median (range).

[^5]: CDR-SB = Clinical Dementia Rating Scale Sum of Boxes; MMSE = Mini-Mental Status Examination; NPI-Q = brief questionnaire version of the Neuropsychiatric Inventory; UPDRS = Unified Parkinson\'s Disease Rating Scale.

[^6]: a Significant differences were observed when including controls, at *P \< *0.05.
